Pharmagen, Inc. Announces Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2013
For the nine months, the company reported total revenues were $3.770 million compared to $3.246 million for the nine months ended September 30, 2012. While this is modest year to date growth, gross profit year to date more than doubled from $1.071 million for the nine months ended September 30, 2012 to $2.404 million for the nine months ended September 30, 2013.